

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Disease models			
Single immunoglobulin and toll-interleukin 1 receptor domain (<i>Sigirr</i> ; <i>Tlr8</i>)-deficient mouse model of <i>Campylobacter jejuni</i> infection	<i>Sigirr</i> -deficient mice could serve as a model to identify new targets to treat <i>C. jejuni</i> infection. Wild-type mice are resistant to pathological infection by <i>C. jejuni</i> . In <i>Sigirr</i> -deficient mice pretreated with vancomycin, <i>C. jejuni</i> induced colonic inflammation, loose stool formation and other symptoms of <i>C. jejuni</i> infection. Also in the vancomycin-pretreated, <i>Sigirr</i> -deficient model, deficiency in <i>toll-like receptor 4 (Tlr4)</i> increased inflammatory responses to infection and deficiency in <i>Tlr2</i> decreased inflammatory responses compared with normal <i>Tlr</i> expression. Planned work includes studying mutant strains of <i>C. jejuni</i> in the model to identify potential therapeutic targets.	Patented by the Cleveland Clinic; available for licensing or partnering	Stahl, M. <i>et al. PLoS Pathog</i> ; published online July 17, 2014; doi:10.1371/journal.ppat.1004264 Contact: Bruce A. Vallance, The University of British Columbia, Vancouver, British Columbia, Canada e-mail: bvallance@cw.bc.ca
<p>SciBX 7(33); doi:10.1038/scibx.2014.994 Published online Aug. 28, 2014</p>			